Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2
Learn how B Cell Antibody Discovery on the Beacon system can rapidly screen human B cell to discover antibodies against difficult targets such as viruses.
What's Inside
In this Poster we discuss:
Rapid identification of antigen-specific antibodies from B cells in less than 1 week.
Screening of frozen human PBMCs will enable identification of anti-viral antibodies from both acute and convalescent human patients exposed to SARS-CoV-2 and other viral pandemics.
Multiple assays for antibody specificity and cross-reactivity will enable down-selection of lead candidates.
The heavy/light chain genes encoding antigen-specific antibodies can be rapidly recovered using OptoSeq BCR.
